CLINICAL_TRIALS trial_result · 2019-10-15

Clinical Trial Update: A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) [Phase 2]

Phase 2 trial of lenvatinib for anaplastic thyroid carcinoma was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Eisai Inc. | Conditions: Thyroid Carcinoma, Anaplastic | Phase 2 | Status: TERMINATED | Results posted: 2019-10-15